SeaStar Medical (ICU) announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has agreed to pay for certain expenses incurred by medical centers treating patients covered by Medicare or Medicaid who are enrolled in the NEUTRALIZE-CRS investigational clinical trial. This follows the company’s first award for reimbursement by the CMS that was granted in July 2024 for qualified patients treated in the ongoing NEUTRALIZE-AKI pivotal clinical trial. “To receive CMS coverage of certain expenses for patients in a clinical trial is rare, with less than 100 per year, and we believe reflects the life-saving potential of our technology,” said Eric Schlorff, SeaStar Medical CEO. “We fulfilled multiple criteria set forth by the CMS for this award, including ten study criteria elements that included assessment of how we could improve health outcomes, how generalizable the Selective Cytopheretic Device therapy would be to the Medicare population, and how the study results would not duplicate existing knowledge.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical files to sell 4.74M shares of common stock for holders
- SeaStar Medical Holding: Strong Buy Rating Backed by Impressive Revenue Growth and Strategic Advancements
- Seastar Medical’s Earnings Call Highlights Growth and Challenges
- SeaStar Medical Reports Strong Q1 2025 Growth
- SeaStar Medical reaches interim enrollment target for NEUTRALIZE-AKI